These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 11088048)
21. Use of an enzymeimmunoassay (EIA) for quantitation of cytosolic and nuclear estrogen receptor, and correlation with progesterone receptor in human breast cancer. Mobbs BG; Johnson IE J Steroid Biochem; 1987 Dec; 28(6):653-62. PubMed ID: 3320574 [TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Bernoux A; de Cremoux P; Lainé-Bidron C; Martin EC; Asselain B; Magdelénat H Breast Cancer Res Treat; 1998 Jun; 49(3):219-25. PubMed ID: 9776505 [TBL] [Abstract][Full Text] [Related]
23. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797 [TBL] [Abstract][Full Text] [Related]
24. Relationship between low estrogen receptor values and other prognostic factors in primary breast tumors. Gaffney EV; Halpin DP; Blakemore WS Surgery; 1995 Mar; 117(3):241-6. PubMed ID: 7878527 [TBL] [Abstract][Full Text] [Related]
25. Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels. Di Fronzo G; Coradini D; Cappelletti V; Miodini P; Granata G; Schwartz M; Panko WB Anticancer Res; 1990; 10(6):1699-705. PubMed ID: 2285244 [TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor and estrogen and progesterone receptors in breast cancers of premenopausal and postmenopausal patients. Skasko E; Paszko Z; Bielińska B; Kluska A Tumori; 1994 Feb; 80(1):56-60. PubMed ID: 8191600 [TBL] [Abstract][Full Text] [Related]
27. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors. Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051 [TBL] [Abstract][Full Text] [Related]
28. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115 [TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Elledge RM; Ciocca DR; Langone G; McGuire WL Cancer; 1993 Apr; 71(8):2499-506. PubMed ID: 8095853 [TBL] [Abstract][Full Text] [Related]
30. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878 [TBL] [Abstract][Full Text] [Related]
31. Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status? Wang N; Wang B; Wang Y; Hu J Breast; 2011 Dec; 20(6):519-24. PubMed ID: 21700456 [TBL] [Abstract][Full Text] [Related]
32. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738 [TBL] [Abstract][Full Text] [Related]
33. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Vrieling A; Buck K; Kaaks R; Chang-Claude J Breast Cancer Res Treat; 2010 Oct; 123(3):641-9. PubMed ID: 20711809 [TBL] [Abstract][Full Text] [Related]
34. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Alexieva-Figusch J; Van Putten WL; Blankenstein MA; Blonk-Van Der Wijst J; Klijn JG Cancer; 1988 Feb; 61(4):758-68. PubMed ID: 3338038 [TBL] [Abstract][Full Text] [Related]
35. An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays. Chapman JW; Mobbs BG; McCready DR; Lickley HL; Trudeau ME; Hanna W; Kahn HJ; Sawka CA; Fish EB; Pritchard KI J Steroid Biochem Mol Biol; 1996 Mar; 57(5-6):323-8. PubMed ID: 8639468 [TBL] [Abstract][Full Text] [Related]
36. Immunological quantitation of nuclear receptors in human breast cancer: relation to cytosolic estrogen and progesterone receptors. Thorpe SM Cancer Res; 1987 Apr; 47(7):1830-5. PubMed ID: 3545455 [TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J; J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604 [TBL] [Abstract][Full Text] [Related]
38. [Factors affecting estrogen and progesterone receptors in primary breast cancer]. Kuno K; Fukami A; Hori M; Kasumi F; Yoshimoto K Gan No Rinsho; 1983 May; 29(6):621-7. PubMed ID: 6876431 [TBL] [Abstract][Full Text] [Related]
39. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347 [TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]